Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199922 | 0.82 | ACE (0.37) | ACEMME | |
| SCHEMBL12747495 | 0.80 | — | — | |
| SCHEMBL13036956 | 0.79 | ACE (0.41) | ACEMMECASP1 | |
| SCHEMBL8278547 | 0.79 | MME (0.30) | ACEMME | |
| SCHEMBL8279386 | 0.79 | MME (0.30) | ACEMME | |
| SCHEMBL10201670 | 0.77 | FKBP1A (0.36) | ACEMME | |
| SCHEMBL8280348 | 0.76 | — | — | |
| SCHEMBL13815133 | 0.76 | ACE (0.46) | ACEMMECASP1 | |
| SCHEMBL10201656 | 0.73 | CASP3 (0.36) | ACE | |
| SCHEMBL8278544 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012430-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-8314141-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7388017-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | HPN, PRSS1, PRSS3 | ACE 65/4885MME 31/4885CASP1 359/4885 |
| US-20130012430-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | HPN, PRSS1, PRSS3 | ACE 65/4885MME 31/4885CASP1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.